乾癬または乾癬性患者でウステキヌマブまたは他の生物学的製剤を開始後の重篤感染症による入院リスク
Arthritis Care Res (Hoboken) 2022 doi: 10.1002/acr.24630
In this investigation it was concluded that other biologics and apremilast were associated with a 1.4- to 3-times higher risk of hospitalisation for serious infections in PsO/PsA patients when compared to ustekinumab. These findings should be considered in the safety profile of these therapies when selecting appropriate treatment regimens in patients with PsO/PsA.
In coming to this conclusion, this study aimed to compare the IRs of hospitalisations due to serious infections in patients with PsO/PsA receiving ustekinumab compared to other therapies.
Keywords:
